日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299

纳武利尤单抗联合雷莫芦单抗治疗复发性间皮瘤的II期临床试验:HCRN-LUN15-299

Dudek, Arkadiusz Z; Xi, Min X; Scilla, Katherine A; Mamdani, Hirva; Creelan, Benjamin C; Saltos, Andreas; Tanvetyanon, Tawee; Chiappori, Alberto

The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma.

PAC-1 与恩曲替尼联合治疗转移性葡萄膜黑色素瘤

Boudreau Matthew W, Tonogai Emily J, Schane Claire P, Xi Min X, Fischer James H, Vijayakumar Jayanthi, Ji Yan, Tarasow Theodore M, Fan Timothy M, Hergenrother Paul J, Dudek Arkadiusz Z